ReviewDiagnostics (Basel, Switzerland)2024
Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) as a Prognostic Biomarker in Acute Kidney Injury: A Narrative Review.
Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Endothelial biomarkers predict kidney and cardiovascular outcomes after acute kidney injury.Clinical kidney journal · 2026Article
- A protein-small molecule conjugate as a bispecific inhibitor of proteases implicated in cancer metastasis.Scientific reports · 2026Article
- Predictors of Acute Kidney Injury and In-Hospital Mortality in Patients With RT-PCR Confirmed Lassa Fever in Southwest Nigeria.Open forum infectious diseases · 2026Article
- Association between intrarenal venous flow and postoperative acute kidney injury in cardiac surgery patients following cardiopulmonary bypass: a prospective cohort study.BMC cardiovascular disorders · 2026Observational
- Renal Biomarkers of Injury as Early Predictors of COVID-19 Associated Acute Kidney Injury: A Prospective Observational Trial (BRICOAKI Study).Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2026Article
- Evaluation of a Novel Biomarker Panel for Acute Kidney Injury Following Endovascular Aortic Repair.International journal of molecular sciences · 2025Article
- Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.Life (Basel, Switzerland) · 2025Review
- Prognostic and diagnostic value of PVR gene and protein levels, serum amylase, and urinary IGFBP-7 and TIMP-2 biomarkers in multiple myeloma.BMC cancer · 2025Article
- Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.International urology and nephrology · 2025Review
- Review
- New Strategies for the Treatment of Diabetic Foot Ulcers Using Nanoenzymes: Frontline Advances in Anti-Infection, Immune Regulation, and Microenvironment Improvement.International journal of nanomedicine · 2025Review
- Application of biomarkers in the diagnosis of kidney disease.Frontiers in medicine · 2025Review
- Outcome in Critically Ill Dogs and Dogs With Acute Kidney Injury Based on Neutrophil Gelatinase-Associated Lipocalin and Tissue Inhibitor of Metalloproteinase-2.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney damage (AKI) is a serious and common consequence among critically unwell individuals. Traditional biomarkers, such as serum creatinine, frequently fail to detect AKI in its early stages, necessitating the development of new accurate early biomarkers. Tissue inhibitor of metalloproteinases 2 (TIMP-2) has emerged as a promising biomarker for predicting early AKI. The present narrative review investigates the role of TIMP-2 in AKI prediction in a variety of clinical scenarios. In the NephroCheck
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.